We’re happy to announce that Algorithm379, a company specializing in developing in silico therapeutics, has chosen Macrogen Europe as their preferred supplier for next generation sequencing (NGS) services.
Algorithm379 helps clients develop multilevel drug discovery platforms that address unmet research and clinical needs. It employs state-of-the-art bioinformatics, cheminformatics and big data analytics platforms to identify new therapeutic targets – and to develop and repurpose robust drug candidates.
Macrogen Europe’s services will support Algorithm379 in delivering a comprehensive, end-to-end offering for R&D and precision medicine projects that reduces drug discovery costs and shortens time to market – to ensure the most impactful solutions for patients.
We look forward to working with them!